Summary of Medical Ethics in Pediatric End-of-Life Care

## Introduction Medical ethics examines moral principles guiding clinical decision-making. This case study focuses on the 2017 Charlie Gard case, which highlights tensions between beneficence, nonmaleficence, and autonomy when parents, physicians, and courts disagree about experimental treatment for a critically ill child. > Definition: Medical ethics — the field that applies moral principles to clinical practice, research, and health policy to protect patients and guide professional conduct. ## Background: The Charlie Gard case (concise timeline) - Born August 2016 at Great Ormond Street Hospital (GOSH), London. - At 8 weeks developed weakness and weight loss; testing identified an RRM2B mutation causing mitochondrial DNA depletion syndrome and an epileptic encephalomyopathy. - Progressive respiratory failure, tetraplegia, seizures; prognosis: death within months. - Parents sought experimental nucleoside replacement therapy used previously for TK2-related mitochondrial myopathy; hospitals in Italy and the U.S. were willing to treat. - GOSH refused treatment/transfer and petitioned UK courts to withdraw ventilatory support; courts upheld GOSH. After prolonged legal battles and deterioration, parents agreed to withdraw care; Charlie died July 2017. ## Core ethical principles (broken down) ### Beneficence - Obligation to act in the patient's best interest and promote wellbeing. - Applied here: would nucleoside therapy likely improve Charlie's condition? Evidence was limited and derived from a different genetic subtype (TK2), which primarily causes myopathy rather than encephalopathy. ### Nonmaleficence - Duty to avoid causing harm. - Considerations: the experimental therapy had no known serious adverse effects in TK2 cases, but treating an infant with severe encephalopathy could prolong suffering if ineffective. ### Autonomy (and surrogate decision-making) - Patients make informed choices; when patients lack capacity, surrogates decide based on the patient's best interests and previously expressed values. - For minors, parents are primary surrogates; courts intervene when medical teams find parental requests contrary to the child’s welfare or medically futile. > Definition: Surrogate decision-maker — an individual authorized to make medical decisions for a patient who lacks decision-making capacity, typically a parent for a minor. ## Applying principles to Charlie Gard - Beneficence: limited preclinical and clinical evidence supported use in TK2 mutations, but efficacy for RRM2B encephalopathy was unknown. - Nonmaleficence: therapy had not shown serious toxicity; main concern was prolonging suffering if condition was irreversible. - Autonomy: parents wished to transfer and pursue treatment; hospital and courts prioritized perceived best interests and futility determinations. Did GOSH have ethical justification to block transfer? - Risks of transfer for ventilated patients are often manageable with trained staff and equipment; precedent (Baby Joseph) shows international transfer is feasible. - Ethically, denying transfer can be seen as restricting surrogate autonomy when a nonmaleficent, potentially beneficent option exists. ## Practical considerations when evaluating experimental therapy 1. Evidence quality: case reports, animal models, or RCTs? For Charlie, evidence was limited to animal studies and TK2 case reports. 2. Risk–benefit ratio: likelihood of benefit vs. probability and severity of harm. 3. Patient values and goals: life prolongation vs. comfort-focused care. 4. Feasibility and logistics: safe transfer, availability of treatment, costs, legal constraints. 5. Regulatory and institutional policies: compassionate use pathways, hospital ethics committees, and court involvement. ## Real-world applications and comparisons - Baby Joseph: illustrates precedent for transfer despite physician opposition; outcome was death 6 months later at home after tracheostomy in the U.S. - Clinical practice lesson: when families